July 1994
Volume 35, Issue 8
Free
Articles  |   July 1994
Effect of LFA-1 and ICAM-1 antibody treatment on murine corneal allograft survival.
Author Affiliations
  • Y He
    Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas 75235.
  • J Mellon
    Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas 75235.
  • R Apte
    Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas 75235.
  • J Y Niederkorn
    Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas 75235.
Investigative Ophthalmology & Visual Science July 1994, Vol.35, 3218-3225. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y He, J Mellon, R Apte, J Y Niederkorn; Effect of LFA-1 and ICAM-1 antibody treatment on murine corneal allograft survival.. Invest. Ophthalmol. Vis. Sci. 1994;35(8):3218-3225.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: To examine the effect of anti-LFA-1 and anti-ICAM-1 antibody treatment on orthotopic corneal graft survival in a mouse model. METHODS: Anti-LFA-1 and anti-ICAM-1 antibodies were administered intraperitoneally before and shortly after orthotopic corneal transplantation. Grafts were observed by biomicroscopy, and survival times were determined. Cytotoxic T lymphocyte (CTL) and delayed-type hypersensitivity (DTH) responses to donor alloantigens were assessed at selected times after grafting. RESULTS: Administration of anti-LFA-1 antibody reduced the incidence of graft rejection from 90% in untreated donors to 47% in anti-LFA-1 treated mice. By contrast, treatment with anti-ICAM-1 antibody alone did not reduce the incidence of rejection, although it prolonged graft survival time. Both CTL and DTH responses to donor alloantigens were severely depressed in hosts treated with either anti-LFA-1 or anti-ICAM-1 antibody. However, neither anti-ICAM-1 nor anti-LFA-1 antibody treatment prevented the rejection of orthotopic corneal grafts in previously immunized mice. CONCLUSIONS: Anti-ICAM-1 antibody does not promote graft survival even though it impairs CTL and DTH responses to donor alloantigens. By contrast, anti-LFA-1 antibody can significantly reduce the incidence of orthotopic corneal graft rejection and prevent the induction of normal allospecific CTL and DTH responses. Although anti-LFA-1 antibody is effective if given prophylactically, it is ineffective at preventing corneal graft rejection in previously immunized hosts.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×